US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance
This economic evaluation demonstrated that LEN+OBR provides meaningful increases in QALYs and LYs, and is dominant over a lifetime time horizon, compared with FTR+OBR and IBA+OBR for the treatment of PWH with MDR in the United States.
Authors
- Dylan J. Mezzio (ORCID: https://orcid.org/0009-0003-8931-6553)
- Lucy A. Eddowes (ORCID: https://orcid.org/0000-0002-9972-8792)
- Vittoria Vardanega
- Emma New
Institutions
- Gilead Sciences (United States) (US)
- Costello Medical Consulting (United Kingdom) (GB)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2024-08-30
- DOI
- https://doi.org/10.18553/jmcp.2024.30.9.1001
- Citations
- 2
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.78